Plain-English translation of NCT06829784 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase III clinical trial testing a medication called TQC2731, which is given as an injection every 4 weeks to treat severe asthma that doesn't respond well to standard asthma medications. Researchers want to see if this treatment can help reduce asthma attacks and improve breathing in adults whose asthma remains poorly controlled despite being on high-dose steroid inhalers and other asthma medicines. Half of the participants will receive the new medication, and half will receive a placebo (a dummy injection) to compare how well it works.
Many people with severe asthma continue to have frequent asthma attacks and breathing problems even when taking the strongest available inhaled steroids and other control medications. This trial is testing whether this new injectable treatment could help these patients breathe better and have fewer serious asthma episodes.
You likely qualify if…
You likely don't qualify if…
If you qualify and are chosen for this trial, you will receive either the new medication or a placebo injection every 4 weeks for 48 weeks (about one year). You'll give yourself the injection at home under the skin, similar to an insulin injection, as part of a regular treatment schedule. Throughout the trial, you'll have regular visits with the research team to check how well the medication is working, monitor for any side effects, and answer questions about your asthma symptoms and any attacks you may have had.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
China